You have no doubt, noticed that IMGN participated in todays spurt. It seems that the trading pattern has changed and Immunogen is on an upper pattern. One year a go it would have been heading south Too many pluses exist for this stock to keep it down. The ride in the next year (up or down) could be very interesting. And the shorts are feeling a wedigie.
This IMGN message board & Investor Village Message board is lately lightly posted. Shorts have been really hurt since this stock has been strong. Downers like that Oppy guy has ceased to post on the Investor Village board and trades have been big. Could be that the garden may be yielding some long term benefits
On page M2 of this weeks Barron's, Immunogen chart showed with the following: At a big oncology conference , a small study reported that half the patients with drug-resistant ovarian cancer responded to the company's treatment. This is a one up for IMGN since Barron's is very conservative of mentioning bio-tech firms.
The dozens of pitiful message posts here really gives you an idea how much shorts have been hurting since Monday. They came out of the wall or should I say out of the woods to post negative messages. Reminds me of a call I received from the I.R.S. (Tel number 202-864-1214) today saying that I need to speak to a representative to pay up my taxes with a credit card number.
For the first time I feel that IMGN will be taken out & in a very short time. $22.00 clams and Roche, Merck or Amgen will have a bargain. It is time for a strong Company to fine-tune the finishing touches to this techknology & send Mr. Junus into the twilight zone.
Holy Toledo. We have some hurting shorts that are in deep depression. Is there a Doctor in the house?
Roche shows strength Amid Uncertainty - December's failure to show new drug Kadcylaa worked better than current treatments was a blow. But if its immunotherapy treatment works well in combinations without toxic side effects, that would be an advantage....wait and see the results at Asche conference.